ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Convergence of Plasmid-Mediated tmexCD-toprJ With Critical Resistance Genes Fuels Spread of Multidrug Resistant Bacteria.
Kaiwen Song, Meng Wang, Xingyu Wu, Meng Cai, Bowen Li, Qi Wang, Xiaodong Guan, Qi Ding, Ruobing Wang, Hui Wang
Abstract read
In one paragraphArticle in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Kaiwen SongDepartment of Clinical Laboratory, Peking University People's Hospital; Beijing Key Laboratory of Innovative & Transformable Warning and Intervention Technologies for Drug-Resistant Pathogens, Beijing, China.
Meng WangDepartment of Clinical Laboratory, Peking University People's Hospital; Beijing Key Laboratory of Innovative & Transformable Warning and Intervention Technologies for Drug-Resistant Pathogens, Beijing, China.
Xingyu WuDepartment of Clinical Laboratory, Peking University People's Hospital; Beijing Key Laboratory of Innovative & Transformable Warning and Intervention Technologies for Drug-Resistant Pathogens, Beijing, China.
Meng CaiDepartment of Clinical Laboratory, Peking University People's Hospital; Beijing Key Laboratory of Innovative & Transformable Warning and Intervention Technologies for Drug-Resistant Pathogens, Beijing, China.
Bowen LiDepartment of Clinical Laboratory, Peking University People's Hospital; Beijing Key Laboratory of Innovative & Transformable Warning and Intervention Technologies for Drug-Resistant Pathogens, Beijing, China.
Qi WangDepartment of Clinical Laboratory, Peking University People's Hospital; Beijing Key Laboratory of Innovative & Transformable Warning and Intervention Technologies for Drug-Resistant Pathogens, Beijing, China.ORCID https://orcid.org/0009-0005-0269-8435 Qi DingDepartment of Clinical Laboratory, Peking University People's Hospital; Beijing Key Laboratory of Innovative & Transformable Warning and Intervention Technologies for Drug-Resistant Pathogens, Beijing, China.ORCID https://orcid.org/0000-0001-8535-1405 Ruobing WangDepartment of Clinical Laboratory, Peking University People's Hospital; Beijing Key Laboratory of Innovative & Transformable Warning and Intervention Technologies for Drug-Resistant Pathogens, Beijing, China.ORCID https://orcid.org/0000-0002-9921-7271 Hui WangDepartment of Clinical Laboratory, Peking University People's Hospital; Beijing Key Laboratory of Innovative & Transformable Warning and Intervention Technologies for Drug-Resistant Pathogens, Beijing, China.ORCID https://orcid.org/0000-0001-9220-0357 Funding
National Key Research & Development Program of China 2023YFC2307100National Natural Science Foundation of China 32141001
6 · The paper itselfAbstract
The plasmid-mediated tigecycline resistance cluster tmexCD-toprJ is an emerging clinical threat whose convergence with carbapenemase and colistin resistance determinants may compromise multiple last-line therapies. We analyzed 1227 tmexCD-toprJ-positive genomes from 42 countries and 16 genera, including 1189 public genomes and 38 newly sequenced clinical isolates. The increase was most pronounced in China, where tmexCD-toprJ prevalence rose from 0.282% before 2011 to 1.504% after 2020, and approximately half of post-2015 Chinese isolates were classified as dual-positive, co-harboring bla
Indexed as
blaKPC/blaNDM/mcrco‐resistanceepidemiologytmexCD‐toprJ
Identifiers
PMID42621686
PMCPMC13491359
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390